There is no single success rate for stem-cell therapy — it depends on the condition, cell type and what counts as success. Here is what the published evidence reports, condition by condition, with trial stage and approval status.
Direct answer: Stem-cell therapy has no single success rate. The strongest, proven results are in haematopoietic transplantation for blood and immune disorders (established, often curative). For most other conditions it remains investigational — “success” usually means slowed progression or symptom improvement in a subset of patients, reported in early-phase trials rather than large randomised studies. Below is the honest, per-condition picture; for context on how to read trial figures, see how to read stem-cell success rates.
Figures on each linked page come from registered clinical trials and published clinic series, not promotional claims. Most uses are investigational; check approval status before booking.
There is no single success rate. Outcomes depend on the condition, the cell type, the study design and how “success” is defined (symptom relief, biomarker change, or cure). Most regenerative therapies are still investigational, so reported figures come from early-phase trials and clinic series rather than large randomised trials. The strongest evidence is in haematopoietic transplantation for blood and immune disorders; for most other conditions, benefit means slowed progression or symptom improvement in a subset of patients, not a cure.
Because “stem cell therapy” covers many cell types and dozens of conditions at very different evidence levels. A figure quoted for knee osteoarthritis says nothing about multiple sclerosis. Honest reporting is condition-by-condition, with the trial stage and what was actually measured — which is how we present it on each condition page.
Haematopoietic stem-cell transplantation is established and curative for selected blood and immune disorders. MSC-based therapy has approved use for perianal fistulae in Crohn’s disease. Orthopaedic uses (knee, joints) and autoimmune conditions show the most promising early-trial data among investigational uses. Always check the approval status and trial stage for your specific condition.
GMP-zertifizierte regenerative Medizin mitten in der EU — ab 3.000–8.000 €, ein Bruchteil der US- oder Deutschland-Preise. Individuelle Protokolle für internationale Patienten aus über 50 Ländern.
Kostenlose ärztliche Prüfung